CRC showed a variety of specificities in the abovementioned results; we, therefore, selected six CRC‐dysregulated metabolic rate‐limiting enzymes (IMPDH1, MYLK, XDH, DPYD, UGDH and PTGS1) for validation in our clinical cohort by qRT‐PCR assays (Figures 5A, S2A and Table S4). This evidence concerns the gene MYLK and colorectal carcinoma.